Moraski Garrett C, Cheng Yong, Cho Sanghyun, Cramer Jeffrey W, Godfrey Alexander, Masquelin Thierry, Franzblau Scott G, Miller Marvin J, Schorey Jeffery
Department of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, USA.
Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5018-22. doi: 10.1128/AAC.00618-16. Print 2016 Aug.
A panel of six imidazo[1,2-a]pyridine-3-carboxamides (IAPs) were shown to have low-micromolar activity against Mycobacterium avium strains. Compound ND-10885 (compound 2) showed significant activity in the lung, spleen, and liver in a mouse M. avium infection model. A combined regimen consisting of ND-10885 (compound 2) and rifampin was additive in its anti-M. avium activity in the lung. Our data indicate that IAPs represent a new class of antibiotics that are active against M. avium and could potentially serve as an effective addition to a combined treatment regimen.
一组六种咪唑并[1,2 - a]吡啶 - 3 - 甲酰胺（IAPs）对鸟分枝杆菌菌株显示出低微摩尔活性。化合物ND - 10885（化合物2）在小鼠鸟分枝杆菌感染模型的肺、脾和肝脏中显示出显著活性。由ND - 10885（化合物2）和利福平组成的联合方案在肺部抗鸟分枝杆菌活性方面具有相加作用。我们的数据表明，IAPs代表了一类对鸟分枝杆菌有活性的新型抗生素，有可能作为联合治疗方案的有效补充。
Zotero 插件